Henderson, Nevada – October 26, 2020 – United Health Products, Inc. (OTC: UEEC), (“UHP” or the “Company”), developer, manufacturer and marketer of HemoStyp, a patented Neutralized Oxidized Regenerated Cellulose (NORC) hemostatic agent, today announced that the London based Journal of Wound Care has informed the Company that UHP’s submitted article, Efficacy and Safety of HemoStyp as an Adjunct for Management of Secondary Hemostasis in the Operative Setting, has been accepted for publication in the November 2020 edition. This peer reviewed article was authored by Raymond Schaerf, MD, Sasan Najibi, MD, John Conrad, MD. and Gerard Abate MD and highlights the results of the study demonstrating HemoStyp’s superiority to Surgicel® Original, the current standard of care produced by Johnson & Johnson’s Ethicon division.
Dr. Gerard Abate, UHP’s Chief Medical Officer stated; “This is the first head-to-head trial of an ORC and an NORC. The data demonstrate that HemoStyp achieved hemostasis in Lewis Bleeding Scale Level 1 and Level 2 bleeding situations faster than Surgicel in all surgical classes studied. Moreover, in Lewis Level 2 scenarios, 20% of patients treated with Surgicel did not achieve hemostasis within the 10-minute test window, while 100% of HemoStyp patients with Level 2 bleeds achieved hemostasis within two minutes. The implications are fewer transfusions, shorter OR times and superior mortality outcomes. Based on this data, upon anticipated PMA approval for class III FDA surgical use, surgeons will have a superior product to utilize for low grade surgical bleeds.”
About Journal of Wound Care – A global leading journal for professionals in wound care, publishing cutting edge evidence-based research enabling its audience to be up to date with the latest in innovation, research, and education in wound care. Double blind peer reviewed, JWC is the only Global wound care journal to be both Pubmed and Medline listed with an impact factor of 1.95, reaching 8,000 clinicians, podiatrists, surgeons, nurses, academics, scientists, and key opinion leaders every month.
About United Health Products –United Health Products develops patented wound care technology; manufactures and markets hemostatic products for the healthcare and wound care sectors. The Company’s main product, HemoStyp is an all-natural product designed to control bleeding. UHP is focused on identifying new markets and applications for its products and expanding its current markets. UHP currently sells a suite of hemostatic products to the dental, veterinary and consumer markets.
Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipates” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.
United Health Products, Inc.
IR Contact : Philippe Niemetz 212-344-6464